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Abstract 
Background: Near-IR fluorescence (NIRF) imaging is becoming a promising approach in preclinical tumor detection 
and clinical image-guided oncological surgery. While heptamethine cyanine dye IR780 has excellent tumor targeting 
and imaging potential, its hydrophobic property limits its clinical use. In this study, we developed nanoparticle formu-
lations to facilitate the use of IR780 for fluorescent imaging of malignant brain tumor.
Methods: Self-assembled IR780-liposomes and IR780-phospholipid micelles were prepared and their NIRF properties 
were characterized. The intracellular accumulation of IR780-nanoparticles in glioma cells were determined using con-
focal microscopy. The in vivo brain tumor targeting and NIRF imaging capacity of IR780-nanoparticles were evaluated 
using U87MG glioma ectopic and orthotopic xenograft models and a spontaneous glioma mouse model driven by 
RAS/RTK activation.
Results: The loading of IR780 into liposomes or phospholipid micelles was efficient. The particle diameter of IR780-
liposomes and IR780-phospholipid micelles were 95 and 26 nm, respectively. While stock solutions of each prepara-
tion were maintained at ready-to-use condition, the IR780-phospholipid micelles were more stable. In tissue culture 
cells, IR780-nanoparticles prepared by either method accumulated in mitochondria, however, in animals the IR780-
phospholipid micelles showed enhanced intra-tumoral accumulation in U87MG ectopic tumors. Moreover, IR780-
phospholipid micelles also showed preferred intracranial tumor accumulation and potent NIRF signal intensity in 
glioma orthotopic models at a real-time, non-invasive manner.
Conclusion: The IR780-phospholipid micelles demonstrated tumor-specific NIRF imaging capacity in glioma preclini-
cal mouse models, providing great potential for clinical imaging and image-guided surgery of brain tumors.
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Background
Non-invasive imaging modalities, such as computed 
tomography (CT), magnetic resonance imaging (MRI), 
single-photon emission computed tomography (SPECT), 
and positron emission tomography (PET) play key 
roles in clinical diagnosis, evaluation of disease sta-
tus and treatment of tumor. The in vivo optical imaging 
technology using near-infrared fluorescent (NIRF) 
probes, due to the low NIR absorption and scattering 
by the tissue, and minimal tissue auto-fluorescence in 
the NIR window (700–900 nm), is becoming a conveni-
ent alternative to the comprehensive imaging modalities 
in preclinical studies for tumor detection [1–4] and is 
showing promising results in clinical image-guided onco-
logical surgery [5–10]. The NIRF dye indocyanine green 
(ICG) has been exploited for imaging of angiogenesis 
and hepatic segments after hepatectomy [5, 6], as well 
as for NIR image-guided surgery in a few cancer types 
[7]. Methylene blue (MB) showed good potential to aid 
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for clinical use [9, 10]. Among other dyes, NIRF hep-
tamethine cyanine dye IR780 was found to have excellent 
intrinsic tumor targeting and imaging properties without 
further modification [11–14], providing great potential 
for tumor NIRF imaging. IR780′s low cytotoxicity makes 
it of potential clinical use; however, it is also hydrophobic 
and insoluble in pharmaceutically acceptable solvents, 
thus an appropriate formulation is required for clini-
cal use [15, 16]. Several formulations of IR780-encapsu-
lated nanoparticles have been investigated, such as the 
heparin-folic acid conjugate [17], biodegradable human 
serum albumin nanoparticles [15], transferrin nanopar-
ticles [16], poly(n-butyl cyanoacrylate) nanocapsules 
[18], poly(styrene-alt-maleic anhydride)-based diblock 
copolymer micelles [19], rhenium-188 labeled meth-
oxy poly(ethylene glycol)-block-poly(ε-caprolactone) 
copolymeric micelles [20], pH-responsive polymeric 
prodrug micelles [21], phospholipid mimicking homopol-
ymeric micelles [22], bubble-generating folate-targeted 
liposomes [23], and amsacrine analog-loaded solid lipid 
nanoparticle [24]. However, most of these carriers were 
designed for both diagnostic and therapeutic purpose, 
rarely for fulfilling the unique requirement of NIRF imag-
ing or tumor detection.
Glioblastoma multiforme (GBM) is the most com-
mon and lethal primary brain tumor lacking effective 
therapeutics due to the invasive growth. The migratory 
tumor cells penetrate into normal parenchyma prevent-
ing its complete surgical removal, and its high resist-
ance to chemotherapy and radiotherapy contribute to 
GBM’s recurrence as a more invasive phenotype [25, 26]. 
Although it is well established that the degree of surgical 
resection directly correlated to patient survival [27, 28], 
most surgery is performed based on the surgeon’s direct 
visualization of the tumor without any image guidance. 
Blood–brain barrier (BBB) and blood–tumor barrier 
(BTB) further challenge the effective treatment of this 
brain tumor, as most chemotherapy reagents fail to ben-
efit the patients due to the lack of penetration into tumor 
tissue [29, 30]. NIRF imaging is expected to benefit the 
preclinical study of GBM and the optical image-guided 
surgery. Phospholipid nanoparticles, including liposomes 
and phospholipid micelles are promising drug carriers, 
which are biocompatible and able to improve the phar-
macokinetics of the encapsulated drug and accumula-
tion in a solid tumor via the enhanced permeability and 
retention (EPR) effect [31–33] In this study, we generated 
two formulations, liposomes and phospholipid micelles 
(Schematic diagram in Fig.  1) to incorporate IR780 
for in  vivo brain tumor imaging using both the human 
GBM xenograft model and the spontaneous mouse 
GBM model. The goal was to develop an appropriate 
formulation of IR780 for pharmaceutically acceptable use 
for clinical imaging and brain tumor detection.
Methods
Chemical and material
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 
N-(carbonyl-methoxypolyethyleneglycol 2000)-1,2-dis-
tearoyl-sn-glycero-3-phosphoethanolamine sodium salt 
(DSPE-PEG2000) were purchased from NOF Amer-
ica Corporation. Cholesterol, IR780 iodide and other 
chemicals were purchased from Sigma-Aldrich. Hoechst 
33,342, MitoTracker were purchased from Molecular 
Probes.
Cell lines and culture
U87MG human glioma cells were from American Type 
Culture Collection (ATCC, Manassas, VA). U87M2/luc 
cells were derived from U87MG that stably overexpress 
firefly luciferase [34]. T98G human glioblastoma cells 
were from ATCC. All cell lines were grown in DMEM 
(invitrogen, CA) supplemented with 10% fetal bovine 
serum (FBS) (Hyclone, UT), 1% penicillin, and 1% strep-
tomycin (invitrogen).
Preparation of IR780‑liposomes and IR780‑phospholipid 
micelles
For IR780-liposome preparation, DSPC, cholesterol and 
DSPE-PEG2000 at a molar ratio of 54.8:40:5 were dis-
solved in chloroform (about 15 mg total lipids/ml); 1 mg/
ml IR780 iodide in ethanol then was added to final 0.2% 
molar ratio of dye to total lipids. The solution was rotary 
evaporated in the dark to dryness in vacuo. The dried 
lipid film was hydrated in nitrogen gas-flushed 0.9% 
saline to a final total lipid concentration of 30 mM, vor-
texed and ultra-sonicated under a nitrogen atmosphere 
for final suspension of the lipid particles. The suspen-
sion was repeatedly extruded 16 times through a 100 nm 
Whatman Nucleopore track-etched polycarbonate mem-
brane at 56 °C. The acquired clear bluish suspension was 
flushed with nitrogen gas, sealed in a glass vial and stored 
at either 4 or −20 °C in the dark.
To prepare IR780-phospholipid micelles, thin lipid 
film composed of DSPC and DSPE-PEG2000 containing 
IR780 (molar ratio, 59.5:40:0.5) was formed in the same 
way as for the liposomes preparation, then hydrated with 
nitrogen gas-flushed 0.9% saline to a final total lipid con-
centration of 15  mM, vortexed and ultra-sonicated at 
56  °C for 15 min under a nitrogen gas atmosphere, and 
extruded through a 100 nm Whatman Nucleopore track-
etched polycarbonate membrane. The acquired clear 
cyan micelle suspension was stored under the same con-
ditions as the liposomes.
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Characterization of IR780‑liposomes 
and IR780‑phospholipid micelles
Particle sizing of IR780‑liposomes and IR780‑phospholipid 
micelles
The particle size distributions of IR780-liposomes and 
IR780-phospholipid micelles were measured with a 
DynaPro dynamic light-scattering system (Wyatt Tech-
nology, CA). Before measurement, the samples were 
diluted with 200  nm membrane-filtered saline to reach 
appropriate signal concentrations.
Near infrared absorption and fluorescence spectra 
of IR780‑liposomes and IR780‑phospholipid micelles
Visible absorption spectra of IR780, IR780-liposomes and 
IR780-phospholipid micelles diluted in PBS, ethanol/PBS 
and PBS/FBS mixtures were measured by a preconfig-
ured UV–visible spectrometer (StellarNet, Inc., FL). The 
near infrared fluorescent spectra were measured using a 
Synergy™ Neo HTS Multi-mode microplate reader (Bio-
Tek, VT).
Stability of IR780‑liposomes and IR780‑phospholipid micelles
IR780-liposomes and IR780-phospholipid micelles 
were aliquoted as stock solution (20×) and kept in the 
dark at 4 or −20  °C. At different time points the ali-
quots were equilibrated at room temperature and fur-
ther diluted with PBS into a working solution (1×). The 
NIR fluorescent signal intensity was measured at Ex/
Em  =  745/815  nm. The stability was determined using 
relative fluorescent intensity (FI/FI0) which was meas-
ured by fluorescent signal intensity of samples stored at 
4 °C (FI) as compared with those stored at −20 °C (FI0).
In vitro cellular uptake of IR780‑liposomes 
and IR780‑phospholipid micelles
T98G and U87MG cells were pre-cultured in a flask with 
DMEM medium supplied with 10% FBS at 37 °C with 5% 
CO2. For cellular uptake experiments, cells were trypsi-
nized and re-seeded on glass coverslips at a density 
of 6 ×  104/cm2 and cultured for another 24  h to reach 



















Fig. 1 Chemical structure of IR780 and schematic diagram of IR780-liposomes and phospholipid micelles. Phospholipid nanoparticles, including 
liposomes and micelles are promising drug carriers, which can improve the pharmacokinetic property of the encapsulated drug and its accu-
mulation and retention in solid tumor via the enhanced intratumoral permeability. The liposomes vesicle is composed of a phospholipid bilayer 
membrane enclosing an aqueous compartment. The phospholipid micelle vesicle has a single layer of phospholipid core with hydrophilic PEG 
chain coating on the surface. The sizes of phospholipid micelles are generally smaller than liposomes. Hydrophobic IR780 can self-assemble into the 
phospholipid bilayer membrane of liposomes and the phospholipid core of micelles during the formation of IR780-nanoparticles
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medium supplied with free IR780 (IR780 stock solution 
in ethanol freshly diluted in PBS), IR780-liposomes or 
IR780-phospholipid micelles with the final IR780 con-
centration at 1 μM IR780. After 30 min of incubation, the 
cells were washed twice with PBS and supplied with fresh 
DMEM medium without phenol red followed by fur-
ther staining with Hoechst 33,342 (10 μg/ml) for 1 h and 
MitoTracker (1  nM) for 10  min. Microscopic images of 
cells washed with cold PBS and then supplemented with 
medium were acquired using a confocal laser scanning 
microscope (Nikon A1 Plus-RSi, Japan). The excitation/
emission wavelengths for fluorescent imaging of Hoechst 
33,342, IR780 and Mitotracker were 350/461, 650/780 
and 554/576 nm, respectively.
GBM tumor models
All studies involve animals were approved by the VARI 
Institutional Animal Care and Use Committee (IACUC). 
To establish U87M2/luc ectopic xenograft tumor model, 
5 × 105 cells in 100 μl of PBS were subcutaneously inoc-
ulated into the flank region of 6-week old nude mice to 
initiate tumor growth. Three weeks after inoculation, 
tumor initiation rate reached 90%. Tumor size was meas-
ured twice a week using a caliper with tumor volume 
(mm3) =  width2 ×  length/2. The ability of IR780-nano-
particles to cross the BBB was tested using the U87M2/
luc orthotopic model as previously described [34]. 
Briefly, mice were inoculated using a stereotaxic frame. 
A burr hole was created through the skull 2 mm poste-
rior to the bregma, 2 mm anterior to the central suture, 
and 3 mm below the meninges; U87M2/luc cells (5 × 105 
cells in 5 μl of PBS) were injected into the brain paren-
chyma. The orthotopic tumor growth was measured 
by bioluminescence signal intensity (BLI). Each mouse 
received an intraperitoneal injection of 100 μl of 30 mg/
ml D-luciferin sodium solution, and images were taken 
after 10  min using an AMI1000 optical imager (Spec-
tral Instruments Imaging, Inc., Tucson, AZ). To induce 
mouse glioma, plasmids pT2/C-Luc/PGK-SB100, pT/
CAGGS-NRASV12, pKT2/CLP-AKT, and pT2/shP53/
GFP4 (provided by Dr. David Largaespada, University of 
Minnesota) were mixed and the intracerebroventricular 
injection was performed as previously described [35]. 
In brief, neonatal mice were placed on ice for 4  min to 
induce anesthesia before being secured in a cooled, 
“neonatal rat” stereotaxic frame (Stoelting, IL) main-
tained at 4–8  °C by a dry ice/ethanol reservoir. A 10  μl 
syringe fitted with a 30 gauge hypodermic needle (12.5° 
bevel; Hamilton, NV) attached to an automatic injector 
(Stoelting, IL) was used to inject plasmids at a flow rate of 
0.7 μl/min into the right lateral cerebral ventricle. A total 
of 2  μg of plasmid DNA (mixed at 1:1:1:1) in 2  μl was 
injected into each mouse to induce spontaneous glioma. 
No incision was made for the injection. The skull of a 
neonate was penetrated with the needle for all injections. 
Growth of the orthotopic tumor was monitored by BLI as 
described above.
NIRF imaging with IR780 incorporated nanoparticles 
in GBM mouse models
Fourteen nude mice bearing U87M2/luc tumors with 
volumes of 122–580 mm3 were divided into three groups 
based on balanced tumor volumes: (1) free IR780 (IR780 
freshly prepared in ethanol/saline (V/V, 1:9) (n  =  4), 
(2) IR780-liposomes, and (3) IR780-micelles (IR780-
liposomes or IR780-phospholipid micelles freshly diluted 
in saline containing 2 nmol of IR780, n = 5). Each mouse 
was intravenously injected via tail vein with 100 μl imag-
ing agent. The sequential whole body NIRF images at 
different time points (5  min, 1, 4, 24, 48, 72, and 96  h 
post injection) were acquired using an AMI1000 optical 
imager (Ex/Em = 745/810 nm, acquisition time: 1 s). At 
two time points, 24  h and 96  h post injection of IR780 
agents, bioluminescent images also were acquired (imag-
ing acquisition time: 10 s) to determine tumor growth.
Five nude mice with four bearing U87M2/luc orthotopic 
tumors and one tumor-free healthy control, and three FVB 
mice bearing spontaneous GBM induced by activation of 
RAS and AKT and Trp53 loss (FVB/NRAS/AKT/shP53) 
[35] were used to evaluate the imaging capacity of IR780-
phospholipid micelles in orthotopic brain tumors. With 
orthotopic tumors, each mouse was intravenously injected 
with 100 μl IR780-phospholipid micelles freshly diluted in 
saline containing 4 nmol of IR780 (U87M2/luc orthotopic 
model) or 6 nmol of IR780 (FVB/NRAS/AKT/shP53 spon-
taneous tumor model). The sequential whole body images 
at different time points were captured following the same 
procedure performed for U87M2/luc ectopic models.
Ex vivo imaging and histological staining
At the end of the in vivo imaging, mice bearing tumors 
were sacrificed, and brain, heart, lung, liver, spleen, stom-
ach, intestine, normal muscle and skin from lumbar were 
dissected for immediate fluorescent photography using 
the AMI1000 optical imager. For histology analysis, mice 
brains were harvested and fixed in 10% neutral-buffered 
formalin and embedded into paraffin blocks and slides 
(20  μm) were cut for H&E staining. For microscopic 
NIRF images, additional brain sections were cut from the 
paraffin blocks. Unstained slides were scanned using the 
Odyssey imager (LI-COR Biosciences) and software suite 
version 3. Settings were optimized for the highest resolu-
tion and power to allow for visualization of both the fluo-
rescent target and non-fluorescent anatomy. Resolution 
was set to 21 microns with no focal offset and excitation 
intensity was set to 6.0 for the 800 nm channel only.
Page 5 of 12Li et al. J Transl Med  (2017) 15:18 
Statistical analysis
All experimental data were shown as mean ± SD unless 
stated otherwise. Comparisons of data between 2 groups 
or among 3 groups were analyzed using independent-
samples t test or one-way analysis of variance (ANOVA) 
at P < 0.05.
Results
Particle sizes of IR780‑liposomes and IR780‑phospholipid 
micelles
The hydrodynamic diameter of freshly prepared IR780-
liposomes was 95.1 ± 2.2 nm with a polydispersion index 
(PI) = 0.078. The hydrodynamic diameter of freshly pre-
pared IR780-phospholipid micelles was 26.4  ±  8.2  nm 
with PI = 0.096 (Additional file 1: Figure S1). The average 
particle size of IR780-liposomes and IR780-phospholipid 
micelles were not significantly changed after stored at 
4 °C in dark over a period of 40 days.
NIR absorption and fluorescence properties 
of IR780‑liposomes and IR780‑phospholipid micelles
The maximum NIR absorption wavelength of IR780 
in ethanol was at 783  nm (Additional file  1: Figure S2). 
Dilution of the IR780 stock solution with water resulted 
in the hypochromatic shift of the absorption band and 
decreased absorbance, probably due to IR780 aggrega-
tion or the molecular stacking of aromatic ring structure 
in aqueous solution, which can be reversed by adding 
ethanol. The insertion of IR780 into liposomes or phos-
pholipid micelles caused the bathochromic shift of the 
absorption band and decreased absorbance (791 nm for 
IR780-liposomes and 793  nm for IR780-phospholipid 
micelles (Additional file 1: Figure S2). Adding ethanol to 
IR780-liposomes or IR780-phospholipid micelles resulted 
in maximal NIR absorption shifted to 783  nm, indicat-
ing the release of IR780 from dissolved nanoparticles. 
Both IR780-liposomes and IR780-phospholipid micelles 
showed broad NIR fluorescent spectrum with maximum 
excitation/emission wavelength at 745/815  nm. (Addi-
tional file 1: Figure S3).
Stability of IR780‑liposomes and IR780‑phospholipid 
micelles
The long term stability of IR780-liposomes and IR780-
phospholipid micelles was evaluated using fluorescence 
signal intensity of samples stored at 4 °C (FI) as compared 
with that stored at −20  °C (FI0) in dark (Fig.  2). While 
both IR780-liposomes and IR780-phospholipid micelles 
showed constant FI0 over the 40-day period, IR780-
liposomes showed decreased FI with time, resulting in a 
significant reduced FI/FI0 =  0.69 at day 40. In contrast, 
IR780-phospholipid micelles showed stable FI/FI0 =  1.0 
during the entire 40  days, demonstrating their superior 
stability as compared with IR780-liposomes.
In vitro cellular uptake of IR780‑liposomes 
and IR780‑phospholipid micelles
We first compared intracellular uptake of free IR780, 
IR780-liposomes, and IR780-phospholipid micelles 
using T98G cells (Fig. 3). All three formulations showed 
the same perinuclear cytoplasmic accumulation after a 
30-min incubation with the cells, and also suggested a 
mitochondrial localization (Fig.  3a). To confirm, T98G 
and U87MG cells cultured with IR780-micelles also were 
dual-stained with Mitotracker (a specific mitochondrial 
marker) and Hoechst 33,342 (a specific nuclear marker) 
followed by confocol microscopy (Fig. 3b). We observed 
strong overlapping signals of IR780-micelles and 
Mitotracker (Fig. 3b, merged), indicating a mitochondrial 
accumulation of IR780-micelles, which is consistent to 
previous reports that preferential accumulation of free 
IR780 dye and liposomal IR780 were found in mitochon-
dria of multiple tumor cells [11, 12, 36]. Therefore, the 
incorporation of IR780 with liposomes or phospholipid 
micelles preserved the same mitochondrial retention fea-
ture as free IR780.
Preferential uptake and retention of IR780‑nanoparticles 
in U87M2/luc ectopic tumors
The in  vivo tumor-specific uptake of free IR780, IR780-
liposomes, and IR780-phospholipid micelles were 
evaluated using the U87M2/luc ectopic tumor model 
(Fig.  4). The tumors were barely visualized at 4  h post 
drug administration, however, were clearly delineated at 














Fig. 2 Relative fluorescent intensity of IR780-liposomes and IR780-
phospholipid micelles. FI/FI0 was measured by fluorescence signal 
intensity of samples stored in the dark at 4 °C as compared with those 
stored in the dark at −20 °C (n = 3, Ex/Em = 745/815 nm). Short bar 
refers to standard deviation
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24–120  h in all three groups. The tumors from IR780-
phospholipid micelles group showed stronger NIRF sig-
nals than those from IR780-liposomes and free IR780 
groups, both of which displayed similar NIRF intensities 
at each time point (Additional file 1: Figure S4), demon-
strating that phospholipid micelle encapsulation is the 
best formulation for IR780 for tumor-specific targeting 
and retention.
The ex  vivo NIRF images taken after the mice were 
euthanized at the end of day 5 further confirmed the 
major accumulation of IR780 in tumors regardless of for-
mulation (Additional file 1: Figure S5). Minor accumula-
tion of IR780 was found in liver, lung, skin and kidneys.
Real‑time NIRF imaging with IR780‑phospholipid micelles 
in GBM orthotopic models
The blood–brain barrier is a natural challenge for drug 
delivery to brain tumors. Because IR780-micelles showed 
the best intratumoral uptake, we further evaluated its 
NIRF imaging capacity using the U87M2/luc orthotpic 
Fig. 3 Mitochondrial localization of IR780 by confocal microscopy. a T98G cells were cultured with different formulations of IR780 for 30 min fol-
lowed by Hoechst 33342 staining. b T98G and U87MG cells cultured with different formulations of IR780 and dual-stained with Hoechst33342 and 
MitoTracker
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model (Fig. 5). After tumor growth was confirmed by bio-
luminescent imaging, IR780-phospholipid micelles were 
injected via tail vein and NIRF images were acquired 
every 24 h for 4 days. Strong fluorescent signal intensity 
with high contrast was observed in mice brain 24 h post 
injection and lasted for at least 4 days, in the same area 
where emitting the bioluminescent signal, demonstrating 
a good intracranial tumor accumulation and retention. 
In contrast, the healthy control mouse did not show sig-
nificant NIRF signal in normal brain. The tumor-specific 
targeting of IR780-micelles was further confirmed by the 
ex vivo imaging with dissected brains and other organs at 
time of necropsy (Fig. 5b, c). The NIRF signal was mainly 
concentrated in the brain tumors rather than surround-
ing normal tissues. Compared to tumor-bearing brain, 
skin and kidneys had minor retention of the dye, and 
other dissected organs only showed faint signals, indi-
cating a low retention of IR780-phospholipid micelles 
(Fig. 5c).
GBM is the most malignant brain tumor due to the 
extensive invasiveness; activation of RAS and AKT via 
receptor tyrosine kinases (RTK) pathways frequently 
occurs in GBM patients [37]. With the Sleeping Beauty 
transposon system, Wiesner et  al. demonstrated that 
Fig. 4 In vivo NIRF imaging of IR780-nanoparticles with U87M2/luc ectopic model. Nude mice bearing U87MG subcutaneous tumors of similar 
size were dosed with free IR780, IR780-liposomes, or IR780-phospholipid micelles via tail vein injection. Post injection, sequential NIRF images were 
taken at each time point as indicated using the AMI1000 optical imager at Ex/Em = 745/810 nm
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dysregulation of the RAS/RTK pathway induced spon-
taneous GBM formation in mouse; embedding lucif-
erase as a reporter gene further allows tumor growth be 
monitored using BLI [35]. We therefore also tested the 
NIRF imaging capacity of IR780-phospholipid micelles 
using this mouse model. We show that overexpression 
of NRAS and AKT induced invasive tumor growth as 
reported previously (Fig.  6a–c) [35]. Abnormal vascula-
ture (Fig. 6d) and anaplastic cell division (Fig. 6d arrows 
and insert) were also observed, indicating a fast growing 
phenotype. From the same mouse, a 6-day consecutive 
bioluminescent and fluorescent imaging was acquired 
after IR780-phospholipid micelles were injected through 
tail vein (Fig. 6e, f ). We show that the NIRF signal with 
high contrast started to show up in the brain on day 2, 
gradually reached peak on day 4, followed by remis-
sion thereafter until the animal was euthanized on day 6 
(Fig. 6e). From the side view at day 3, the fluorescent and 
bioluminescent imaging clearly showed co-localization 
of the signals (Fig.  6f ), demonstrating a tumor-specific 
accumulation and retention of IR780-phospholipid 
micelles. Consistent to the in vivo imaging results, NIRF 
imaging of brain sections using un-stained paraffin slides 
showed strong fluorescent signal intensity enriched in 
tumor area (Fig.  6b), supporting that IR780-phospho-
lipid micelles can penetrate BBB and accumulate in brain 
tumors.
Discussion
Molecular imaging focuses on the noninvasive quantita-
tion and real-time visualization of molecular processes 
as they occur in  vivo, and NIRF imaging is becoming 
an attractive approach for tumor detection in preclini-
cal animal studies and image-guided resection in clini-
cal oncological surgery. The hydrophobic IR780 iodide 
is a promising tumor-specific targeting NIRF probe 
[12, 13, 38]. Because IR780 is a weak positively-charged 
lipophilic molecule, we envisioned it to intimately inter-
act with the weak anionic phosphate moiety of phos-
pholipid and therefore can be stably packaged within 
Fig. 5 In vivo NIRF imaging of IR780-phospholipid micelles with the U87M2/luc orthotopic model. a Nude mice bearing U87M2/luc orthotopic 
tumors were dosed with IR780-phospholipid micelles via tail vein injection. Post injection, sequential BLI and NIRF images were taken at each time 
point as indicated using the AMI1000 optical imager at Ex/Em = 745/810 nm. Note that the healthy control mouse (the 1st one on the left) did not 
show any signals. b NIRF image of dissected mouse brains after the last whole body imaging. c Representative NIRF image of dissected brain and 
other organs from a mouse bearing U87M2/luc orthotopic tumor. Upper brain, lung, heart and liver; Middle spleen, kidneys, stomach and intestines; 
Lower muscle, skin
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the phospholipid nanoparticles (Fig.  1) during their 
self-assembled formation. To develop an appropriate 
formulation for biomedical use of IR780, we formu-
lated IR780-liposomes and phospholipid micelles each 
carrying 0.2 molar % and 0.5 molar % of IR780. Higher 
molar ratios of dye were avoided to prevent the severe 
fluorescent quenching upon aggregation of dye inside 
the nanoparticles. Both preparations were homogene-
ously dispersed suspensions and showed narrow particle 
size distribution; the particle size of IR780-phospho-
lipid micelles was much smaller than IR780-liposomes 
(26.4  ±  8.2 versus 95.1  ±  2.2  nm), indicating a better 
potential to cross the BBB and BTB. Notably, the inser-
tion of lipophilic IR780 into liposomes or phospho-
lipid micelles reached 100% during the preparation 
and required no further purification step. Comparing 
with IR780-liposomes, which gradually lost NIRF sig-
nal intensity over time, IR780-micelles were very stable, 
and therefore, encapsulation into micelles is a better for-
mulation for IR780. In addition to phospholipids, cho-
lesterol also serves as a major lipid component which 
facilitates the liquid-ordered structures and stabilizes 
the bilayer of the liposome structure [39, 40]. We there-
fore tested the compatibility of free IR780 dye with the 
phospholipid and cholesterol in aqueous suspension, 
respectively. While DSPC strongly adsorbed free IR780 
from aqueous suspension after severe vortexing and 
centrifugation, cholesterol showed no adsorption ability 
with free IR780. This incompatibility of cholesterol with 
IR780 may be the cause of the lower stability of IR780-
liposomes compared to IR780-micelles.
GBM is the most devastating brain tumor invading 
normal brain tissue and escaping surgical eradication; 
most chemotherapeutic reagents lack of permeability 
across the BBB and BTB, further limiting the options of 
effective therapeutics. Developing nanoparticle-incorpo-
rated NIRF dyes not only may improve the brain tumor 
imaging for tumor detection, but also can aid GBM sur-
gery in the operation room to define the invasive boarder. 
Among the NIRF probes that are under development, 
ICG and MB are FDA approved for clinical use, although 
both are blood pool agents that are not specific for any 
tumor tissue [3]. In contrast, IR780 has intrinsic tumor-
targeting activity [13, 14, 41], and the potential to work 
as a sonosensitizer for sonodynamic therapy in cancer, 
suggesting its dual-role as both an imaging probe and an 
anti-cancer reagent [42]. Using T98G and U87MG cells, 
we demonstrate that IR780-liposomes and IR780-phos-
pholipid micelles acted the same as free IR780 that mech-
anistically functions through mitochondrial (Fig. 3). The 
5-day NIRF imaging using the U87M2/luc ectopic model 
further verified the preferential uptake and accumulation 
of IR780-liposomes and IR780-phospholipid micelles 
in brain tumor, where the micelles displayed relatively 
stronger IR780 intratumoral accumulation and reten-
tion. Moreover, no significant uptake and accumulation 
of IR780-phospholipid micelles was observed in brain tis-
sues from normal (Fig. 5 and Additional file 1: Figure S6) 
or ectopic tumor-bearing mice Fig. (4), indicating normal 
brain is not a targeting organ of IR780.
Fig. 6 Real-time NIRF imaging of IR780-phospholipid micelles using 
the GBM spontaneous mouse model. a Representative GBM tumor 
section showing invasive tumor growth in H&E staining. b A duplicate 
unstained brain section showing tumor targeting of IR780-phospho-
lipid micelles by NIRF microscopic imaging. GBM hallmarks including 
invasive tumor growth penetrating into normal brain (c), and anaplas-
tic nuclear (arrowed yellow and insert) and glomeruloid body-like 
vascular structure (arrowed red, d). e Whole-body bioluminescent 
and NIRF imaging of a tumor-bearing mouse at different times post 
injection of IR780-phospholipid micelles. f Intratumoral accumula-
tion of IR780-micelles at day 3 post injection as imaged in the lateral 
position. Note that bioluminescence and fluorescence signals come 
from same area
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While the BBB is a natural challenge for drug deliv-
ery to brain tumors, our results show that IR780-phos-
pholipid micelles could efficiently reach U87M2/luc 
orthotopic tumors 24  h post injection. Potent fluores-
cent signal intensity was found mainly at the tumor area, 
indicating a specific tumor targeting and accumulation 
(Fig.  5). The NIRF imaging with the spontaneous GBM 
mouse model (Fig.  6) showed consistent results to that 
with the U87M2/luc orthotopic model, further demon-
strating that IR780-phospholipid micelles could pene-
trate the BBB and BTB in targeting invasive GBM.
While the results from our preclinical studies have dem-
onstrated that IR780-phospholipid micelles, combining 
the passive tumor targeting feature of nanoparticles via 
EPR effect [33] and the intrinsic tumor-targeting feature of 
IR780, is a promising candidate nanomedicine for tumor 
imaging and image-guided surgery, there are also chal-
lenges prevent its clinical translation. Compared to UV 
and visible light, NIR light has its advantage by deep pen-
etration in biological tissues, however, the skin penetra-
tion remains a major challenge. Recent studies suggest that 
NIRF may penetrate skin, but the optical NIRF signal can 
be affected by the different skin components [43, 44]. With 
ICG, a NIRF dye shares similar optical property to IR780, 
the depth of penetration for NIR fluorescence is estimated 
to be between 2 and 4  cm and could be improved if the 
noise floor of devices could be reduced [45]. Thus, NIRF 
imaging using IR780-micelles will have similar limitations 
for detecting glioma and other types of cancer, whereas 
further studies addressing NIRF light absorption, scatter-
ing, transmission and reflection in context of different skin 
components are required to improve its clinical transla-
tion. Developing NIRF instrumentations with optimized 
light source and detectors can further enhance the capac-
ity of NIRF as a non-invasive imaging modality in clinics. 
Unlike mouse skull, human skull is more solid and tumors 
are more in depth. As IR780 is expected to have limitation 
in penetration through the skull, it will not be a good clini-
cal option for non-invasively imaging brain tumor patients, 
although it remains a valuable tool for imaging pre-clinical 
intracranial tumor models. However, such a disadvan-
tage does not reduce its potential value to facilitate inva-
sive tumor imaging and clinical image-guided oncological 
surgery. NIRF imaging can be used to indicate invasive 
margin during brain tumor resection, or to identify local 
invasion and metastatic lesions for other types of cancer.
Conclusion
In summary, we prepared IR780 carrying liposomes and 
phospholipid micelles and investigated their potential as 
biomedically acceptable agents for brain tumor imaging. 
The IR780-phospholipid micelles were more stable than 
the IR780-liposomes. Both nanoparticles showed good 
NIRF imaging with the GBM ectopic xenograft model. 
Moreover, the IR780-phospholipid micelles also showed 
preferential uptake in the human GBM orthotopic mouse 
model and the spontaneous mouse GBM model, demon-
strating good preclinical and clinical potential for sensi-
tively imaging brain tumors and other types of cancer. In 
the future, it is worthwhile to further explore the NIRF 
imaging capacity of IR780-phospholipid micelles in 
detecting small and early stage tumors in different cancer 
types, by which individual mouse bearing small ectopic 
and orthotopic tumors are to be imaged for evaluation.
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